Navigation Links
Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
Date:7/8/2009

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it will hold a teleconference at 11:00 a.m. Eastern Time tomorrow, Thursday, July 9, to discuss its second major global partnership deal in the past six months, this time for betrixaban, the company's investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF). The company also will provide an update on its pipeline and corporate strategy.

Teleconference Details

To participate in the live call on Thursday, July 9, at 11:00 a.m. Eastern Time, please dial 866-454-4208 from the United States or +1-913-312-1266 internationally. The call will be available as a replay for the next two weeks under the News and Events section of Portola's Web site. To access the replay, please dial 888-203-1112 from the United States or +1-719-457-0820 internationally. The passcode for the replay is 5053448.

About Betrixaban

Betrixaban is an oral Factor Xa inhibitor that has been specifically designed for chronic, once-a-day treatment with a long half-life. Betrixaban is minimally excreted through the kidneys and is the only new oral anticoagulant currently being studied in patients with severe and moderate renal impairment without dose adjustment. As a result, it has the potential to become the only novel oral anticoagulant available for patients with severe renal disease. In addition, betrixaban is not extensively metabolized by cytochrome P450, which may result in reduced potential for drug-drug interactions.

Portola is currently conducting EXPLORE-Xa, a Phase II dose-ranging clinical trial evaluating betrixaban for stroke prevention in 500 patients with atrial fibrillation (SPAF), which is scheduled to be fully enrolled by the end of 2009.

In addition to SPAF, betrixaban could be further developed in other indications, including the treatment or prevention of life threatening blood clots in patients undergoing high-risk orthopedic and general surgery, those with acute and chronic medical illness, and in patients with acute coronary syndrome (ACS).

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. Portola's two lead Phase 2 compounds, betrixaban, an oral Factor Xa inhibitor, and elinogrel, a P2Y12 ADP receptor antagonist, target the global multi-billion dollar antithrombotic market. Both product candidates have best-in-class features versus current products and novel agents in development and address the hospital, specialty and chronic care markets. The company has a global development and commercialization agreement with Novartis for elinogrel, a potential competitor for Plavix (clopidogrel).

Portola also has proprietary pipeline programs focused on the discovery and development of novel, specific Syk and JAK inhibitors to treat cancer and inflammatory diseases; a thromboxane receptor antagonist, which is an aspirin replacement product for patients intolerant to aspirin; and a novel anticoagulant antidote program with the potential to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... ... reminds us that May is National Stroke Awareness Month. According to the Centers for ... the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes occur ... A stroke is when blood flow to the brain is blocked or when a ...
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... A ... were typical among 18 states studied, the Workers Compensation Research Institute (WCRI) ... The WCRI study, CompScope™ Benchmarks for Kentucky, 16th Edition , found that indemnity ...
(Date:4/28/2016)... ... April 28, 2016 , ... SyncDog, Inc. ... its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First ... this will be MobileIron’s 6th Mobile First Conference and will feature immersive training, ...
(Date:4/28/2016)... ... 2016 , ... For the 10,000 Americans who turn 65 on any given ... overall well-being: mental health. Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; ... which can include everything from honing your memory and managing stress to eating healthy ...
(Date:4/28/2016)... , ... April 28, 2016 , ... The USDA recently ... based on the latest nutritional science. While there is a lot of information available ... health, according to the April 2016 issue of Harvard Men's Health Watch . ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Transparency Market ... Devices Market - Global Industry Analysis, Size, Share, Growth, ... report, the global skincare devices market was valued at ... expand at a CAGR of 10.1% from 2015 to ... Browse the full Skincare Devices Market (Treatment Device - ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: SHPG ... will present at the Deutsche Bank 41st Annual Health Care ... May 04, 2016, 10:00 am EDT (15:00 BST). ... and Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/ ... on this same website for approximately 90 days. ...
(Date:4/27/2016)... 27, 2016 The global  ... 2.06 billion by 2022, according to a new ... awareness towards a healthy lifestyle is expected to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... rising health treatment expenditure has urged consumers to ...
Breaking Medicine Technology: